What's Happening?
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. presented pivotal Phase II study results of lunbotinib fumarate at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The study focused on advanced RET fusion-positive non-small
cell lung cancer (NSCLC) and demonstrated robust clinical activity in both treatment-naïve and pre-treated patients. The drug showed significant intracranial efficacy in patients with CNS metastases. Lunbotinib fumarate is a next-generation selective RET inhibitor, and its New Drug Application (NDA) has been accepted for review by the National Medical Products Administration (NMPA) of China.
Why It's Important?
The presentation of lunbotinib fumarate's Phase II data is significant as it offers a promising new treatment option for patients with RET fusion-positive NSCLC, a condition with limited therapeutic options. The drug's efficacy in CNS metastases is particularly noteworthy, addressing a critical need in cancer treatment. The acceptance of the NDA by the NMPA indicates potential market approval, which could expand treatment options for patients in China and potentially globally, impacting the pharmaceutical industry and patient care standards.
What's Next?
Following the presentation at ASCO, the next steps involve the review of the NDA by the NMPA, which could lead to market approval in China. Additionally, ongoing clinical trials in the United States, United Kingdom, Europe, and UAE will further evaluate lunbotinib fumarate's efficacy and safety, potentially leading to broader international approval and commercialization.
